University of Groningen

AKI

Zijlstra, Jan G; van Meurs, Matijs; Moser, Jill

Published in:
Kidney International

DOI:
[10.1016/j.kint.2020.03.016](https://doi.org/10.1016/j.kint.2020.03.016)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Zijlstra, J. G., van Meurs, M., & Moser, J. (2020). AKI: an enlightening acronym with a shadow side. *Kidney International*, 97(6), 1301. <https://doi.org/10.1016/j.kint.2020.03.016>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

The author replies: Stratil¹ cites the influence of both our publication² and its accompanying commentary³ on the recent decision by the German Parliament not to implement a presumed consent model for organ donation, believing our study limitations led to flawed decision-making by the Bundestag.

In response to the specific points made in the letter, we note the following. First, our main analysis did indeed utilize the latest year of available data (2016), but we also conducted additional work utilizing 5 years of cumulative data (2012–2016), with no change in outcomes. Second, we clearly justify categorizing Spain as an opt-in country, a choice with which the Spanish would agree,⁴ but sensitivity analyses are shown for both categorizations. Third, we avoid bias in our statistical approach by utilizing forward stepwise multiple linear regression models to avoid cherry-picking variables. Finally, we specifically avoid making any causal link with any associations, and state “. . . as with any observational data, association does not automatically imply causality, and we caution against such interpretation of our data. Numerous pitfalls with regards to insufficient control for confounders or selection bias can affect observed associations such as the link between opt-out countries and reduced living donor rates.”²

Organ donation rates in Germany are some of the lowest in the developed world, owing to multifactorial reasons, and are genuinely concerning. However, simple legislative tinkering of explicit versus presumed consent will not achieve meaningful change on its own, as shown by both empirical research analysis and real-world evidence. We stand by our conclusion that interventions beyond short-sighted legislation change are warranted to boost organ donation.

1. Stratil JM. Evidence-based decision-making? On the limitations of Arshad et al.'s study used to justify political opinions on organ donation in Germany. *Kidney Int.* 2020;97:1300.
2. Arshad A, Anderson B, Sharif A. Comparison of organ donation and transplantation rates between opt-out and opt-in systems. *Kidney Int.* 2019;95:1453–1460.
3. Matesanz R, Domínguez-Gil B. Opt-out legislations: the mysterious viability of the false. *Kidney Int.* 2019;95:1301–1303.
4. Matesanz R, Marazuela R, Coll E, et al. About the opt-out system, live transplantation, and information to the public on organ donation in Spain . . . Y olé! *Am J Transplant.* 2017;17:1695–1696.

Adnan Sharif^{1,2}

¹Department of Nephrology and Transplantation, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK; and ²Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK

Correspondence: Adnan Sharif, Department of Nephrology and Transplantation, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2WB, United Kingdom. E-mail: adnan.sharif@uhb.nhs.uk

Kidney International (2020) **97**, 1301; <https://doi.org/10.1016/j.kint.2020.02.031>

Copyright © 2020, International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

AKI: an enlightening acronym with a shadow side

To the editor: Skrypnik *et al.*¹ describe elegantly and convincingly that in ischemic acute kidney injury (AKI) in mice, interleukin-6 mediates the production of neutrophil gelatinase-associated lipocalin in the liver and not in the kidney. They extend and generalize this finding to AKI of all etiologies, especially sepsis-induced AKI, in their title and discussion. The AKI concept has advantages for epidemiologic studies, yet this symptom-based definition does not account for etiology or associated pathophysiological mechanisms. Considerable evidence now suggests that the pathophysiological mechanisms of sepsis-induced AKI are different from those seen in AKI of other etiologies.² Moreover, sepsis-induced AKI is a heterogenous syndrome driven by multiple different mechanisms acting simultaneously, but not all to the same extent or at the same time in individual patients.³ We previously identified heterogeneous neutrophil gelatinase-associated lipocalin mRNA and protein levels in kidneys of patients with lethal sepsis.⁴ Hence, clearly not all AKIs are alike, and even within a common etiology of AKI, such as sepsis-induced AKI, heterogeneous findings can be found. Using the name AKI makes talking about it easier as if we understand it. However, it can blur our vision of the details.

1. Skrypnik NI, Gist KM, Okamura K, et al. IL-6-mediated hepatocyte production is the primary source of plasma and urine neutrophil gelatinase-associated lipocalin during acute kidney injury. *Kidney Int.* 2020;97:966–979.
2. Zarbock A, Gomez H, Kellum JA. Sepsis-induced acute kidney injury revisited: pathophysiology, prevention and future therapies. *Curr Opin Crit Care.* 2014;20:588–595.
3. Aslan A, van den Heuvel MC, Stegeman CA, et al. Kidney histopathology in lethal human sepsis. *Crit Care.* 2018;22:359.
4. Jou-Valencia D, Koeze J, Popa ER, et al. Heterogenous renal injury biomarker production reveals human sepsis-associated acute kidney injury subtypes. *Crit Care Expl.* 2019;1:e0047.

Jan G. Zijlstra^{1,2}, Matijs van Meurs^{1,2} and Jill Moser^{1,2}

¹Department of Pathology and Medical Biology, Medical Biology Section, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; and ²Department of Critical Care, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

Correspondence: J.G. Zijlstra, Department of Critical Care, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands. E-mail: j.g.zijlstra@umcg.nl

Kidney International (2020) **97**, 1301; <https://doi.org/10.1016/j.kint.2020.03.016>

Copyright © 2020, International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

The author replies: We agree entirely with the comments by Zijlstra *et al.*,¹ who note that the heterogeneity of different causes of acute kidney injury (AKI), particularly sepsis-induced AKI, can be misrepresented by the use of the general term AKI. The complex nature of AKI demands more precise terminology—and we note that the term AKI itself can be utterly